ARO-C3 is an investigational RNA interference therapeutic designed to reduce liver production of complement component 3 as a potential therapy for various complement-mediated diseases.

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...